Adicet Bio Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

MENLO PARK, Calif. & BOSTON --(BUSINESS WIRE)--Apr. 27, 2022-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that updated safety and efficacy data from the Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin’s Lymphoma (NHL) will be delivered as an oral presentation at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago and online June 3-7, 2022 . Details of the oral presentation are as follows: Abstract Number : 7509 Abstract Title : A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta (γδ) t cells in adults with B-cell malignancies Presenting Author : Sattva Neelapu, MD, MD Anderson Cancer Center Session Type/Title : Clinical Science Symposium/ Beating Bad Blood: The Power of Immunotherapy in Hematologic Malignancies Date : June 6, 2022 Time : 8:00 AM-9:30 AM CDT The abstract will be available on Thursday, May 26 at 5:00 PM EDT on ASCO.org . About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with CAR and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com . View source version on businesswire.com : https://www.businesswire.com/news/home/20220427005290/en/ Adicet Bio., Inc. Investor and Media Contacts Anne Bowdidge [email protected] Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200 [email protected] Source: Adicet Bio, Inc.

The release as fetched from its publisher. adicetbio.com ↗